Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verdant phase 2 study of ARGX-121 SC in adults with primary IgA nephropathy
jRCT2031260526Phase 2Recruiting
- Sponsor
- argenx
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing ARGX-121 with Placebo followed by ARGX-121 (2 arms). Primary endpoint: Change in proteinuria from baseline to week 24. Started Sep 2026; status: recruiting.
02
Drugs
ARGX-121
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2031260526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260526.